Skip to main content

The independent medical news service

Thomas John

28-09-2020 | Neuro-oncology | Video

ESMO 2020 | Entrectinib has durable CNS activity in patients with NTRK fusion-positive tumors

Thomas John discusses a pooled analysis of data from three early-phase trials showing the intracranial efficacy of entrectinib in patients with solid tumors and central nervous system metastases (5:33).

18-07-2019 | Oncology | News | Article

Genomic markers of brain metastasis risk identified in NSCLC

Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.

26-06-2019 | Oncology | News | Article

Nivolumab has ‘limited’ CNS activity in RCC patients with brain metastases

In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.

24-05-2019 | Oncology | News | Article

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

26-03-2019 | Oncology | News | Article

Pachymeningeal seeding possible after brain metastases resection

Neurosurgical resection of brain metastases followed by stereotactic radiation can lead to pachymeningeal seeding outside of the stereotactic radiation field, according to findings reported in JAMA Oncology.

27-08-2018 | Oncology | News | Article

Bevacizumab strikes out in recurrent glioma

The outcomes of patients with a first recurrence of WHO grade II or III glioma without the 1p/19q co-deletion are not improved when bevacizumab is added to the standard of care temozolomide, suggest phase II trial findings.